Brief: Ngm Bio Announces Oral Plenary Presentation Of Data From Phase 2B Alpine 4 Trial Of Aldafermin
11/10/2023 21:49
Oct 11 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES ORAL PLENARY PRESENTATION OF DATA FROM
PHASE
2B ALPINE 4 TRIAL OF ALDAFERMIN IN COMPENSATED CIRRHOSIS (F4)
DUE TO NASH AT UPCOMING AASLD THE LIVER MEETING®
Source text for Eikon: ID:nGNX8CWFrW
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors